Jeffrey Miller, MD, on Engaging NK Cells in Solid Tumors


The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.

“We learned [in a previous study] that the immune engager to the NK cell is critically important. And while that study was ongoing, we discovered that if we took a nanobody, single domain antibody to engage CD16, we had significantly greater potency. So that's really the premise for putting this together.”

GTB-5550, a B7H3 tri-specific killer engager (TriKE) specifically stimulated expansion of natural killer (NK) cells in preclinical models of multiple cancers. These data were presented at the European Society of Medical Oncology (ESMO) Congress 2022, held September 9-13, in Paris, France, by Jeffrey Miller, MD, professor and deputy director of the Masonic Cancer Center of the University of Minnesota.

GTB-5550 is a novel dual camelid (cam) TriKE that contains wild type interleukin-15 as well as 2 cam engagers to target CD16 on NK cells and B7H3 on multiple solid tumors. Miller and colleagues demonstrated increased activity of NK cells against cancer cells after stimulation with the TriKE engager.

CGTLive spoke with Miller to learn more about the study’s results and the importance of improving targeting and engagement of NK cells with antibodies. He also discussed the potential for a clinical trial in the near future investigating the approach.

Click here to read more coverage of ESMO Congress 2022.

Miler JS, Zorko N, Merino A, et al. B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells. Presented at: ESMO Congress 2022, September 9-13, Paris, France.
Related Videos
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
Related Content
© 2023 MJH Life Sciences

All rights reserved.